TG Therapeutics' U2 combo + chemo shows positive action in early-stage lymphoma study; shares up 2%

|About: TG Therapeutics, Inc. (TGTX)|By:, SA News Editor

Updated data from a Phase 1/1b clinical trial evaluating TG Therapeutics' (TGTX +2.2%) ublituximab, a glycoengineered anti-CD20 monoclonal antibody, combined with PI3K delta inhibitor umbralisib (TGR-1202) (called "U2") and chemo agent bendamustine, in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) showed a treatment effect. The results were presented at ASH in San Diego.

38 patients were evaluable for efficacy. The overall response rate (ORR) in DLBCL patients was 48% (n=12/25), including nine complete responders. The ORR in FL patients was 85% (n=11/13), including seven complete responders.

Previously: TG Therapeutics up 7% on positive umbralisib + ublituximab data (Nov. 1)


Subscribe for full text news in your inbox